Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

TENS

TENS · Electrical Pain-Gating Therapy

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

381 human trials, about 500 studies, 24,532 participants in the 2022 meta-TENS pooled analysis of 381 RCTs. The written rationale for this grade is still being prepared.

FDA
FDA Class II under 21 CFR 882.5890; cleared via 510(k). Available both over-the-counter (general and arthritis pain) and by prescription. New units clear on substantial equivalence, usually without fresh efficacy trials.
WADA
Not a prohibited substance or method; TENS is permitted in and out of competition under the WADA Code.

Reference only. Not medical advice.

What can go wrong

Generally low-risk. Most reports involve skin irritation or redness under the electrodes. Do not place electrodes over the front or sides of the neck, the eyes, the mouth, broken or numb skin, or directly over the spine. People with a cardiac pacemaker or other implanted electronic device, a seizure disorder, deep vein thrombosis, or active cancer in the area should not use TENS without clinician sign-off, since interference and uncertain effects have not been ruled out. In pregnancy, TENS should be used only with clinician guidance and should not be applied over the abdomen or low back; anyone who is pregnant or managing a pregnancy-related pain question should consult a qualified provider such as a midwife or physician before use. TENS treats a symptom, not a cause. Unexplained, severe, new, or worsening pain should be evaluated by a clinician rather than self-managed with a device.

TENS sends low-voltage electrical pulses through skin electrodes to change how pain signals reach the brain. Its modern rationale traces to the gate control theory published by Ronald Melzack and Patrick Wall in Science in 1965, which proposed that non-painful sensory input can close a spinal gate and reduce transmission of painful input at the dorsal horn. Conventional high-frequency TENS is thought to recruit this gating, while low-frequency settings appear to trigger release of the body's own opioids; animal work from Kathleen Sluka's group shows low-frequency TENS analgesia is reversed by naloxone, which fits the opioid account, so the mechanism is among the better-characterized parts of the field. Clinical results are more uneven. The overview of Cochrane Reviews led by William Gibson in 2019 rated the underlying evidence very low quality and could not say whether TENS helps chronic pain, and the 2019 American College of Rheumatology osteoarthritis guideline recommends against it for knee and hip OA. Against that, the meta-TENS analysis by Mark Johnson and colleagues (BMJ Open, 2022) pooled 381 randomized trials and found moderate-certainty evidence that TENS lowers pain intensity during and just after stimulation, with a standardized mean difference near -0.96. The gap comes down to how trials were grouped, dosing, blinding, and when pain was measured. TENS is drug-free, low-risk, and patient-controlled, which keeps it in wide use in physiotherapy and at home. It is understood as symptomatic relief, not a treatment for the underlying condition.

Skin-surface electrical stimulation that aims to dampen pain signaling; mechanism is well grounded, clinical results vary

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Short-term relief of localized musculoskeletal and joint pain
  • Adjunct in physiotherapy and post-exercise soreness management
  • Labor pain and some postoperative pain protocols under clinician guidance
  • A drug-sparing option for people limited by analgesic side effects
  • Symptom relief in some neuropathic pain, including diabetic peripheral neuropathy, where results are variable

What people get wrong

  • Often saidTENS cures the underlying injury or disease.

    ActuallyIt modulates pain signaling for symptom relief only. The mechanism work of Melzack and Wall (1965) and the Sluka group supports pain gating and opioid-mediated analgesia, not tissue healing.

  • Often saidThe science shows TENS reliably relieves chronic pain.

    ActuallyThe evidence is mixed. The Gibson 2019 overview of Cochrane Reviews found very low-quality evidence and no confident conclusion for chronic pain, while the Johnson 2022 meta-TENS study found moderate-certainty short-term benefit measured mainly during or right after stimulation.

  • Often saidA pricier device works much better.

    ActuallyNo strong head-to-head evidence shows expensive wearables outperform basic units. The FDA clears most TENS devices on substantial equivalence to existing products under 21 CFR 882.5890, not on comparative efficacy trials.

  • Often saidGuidelines endorse TENS for arthritis pain.

    ActuallyThe 2019 ACR and Arthritis Foundation guideline strongly recommends against TENS for knee and hip osteoarthritis, citing small, low-quality trials with inconsistent controls.

Who profits, and who pushes back

  • William Gibson

    Pushes backLead author, overview of Cochrane Reviews of TENS for chronic pain (2019)

    There was insufficient evidence about the effectiveness and safety of TENS to reduce pain in adults with chronic pain, and the quality of the evidence within the included reviews was very low.

  • 2019 ACR and Arthritis Foundation osteoarthritis guideline panel

    Pushes backKolasinski and colleagues, guideline authors, Arthritis and Rheumatology

    TENS is strongly recommended against in patients with knee or hip osteoarthritis, because studies were of low quality, small in size, and used variable controls, and demonstrated a lack of benefit.

  • Cochrane labor-pain review team

    Pushes backBedwell, Dowswell, Neilson and Lavender, Cochrane review of TENS for labor pain

    There is only limited evidence that TENS reduces pain in labour, and it does not seem to have any impact, positive or negative, on other outcomes for mothers or babies.

  • Mark I. Johnson

    Promotes itPain researcher, lead author of the meta-TENS analysis

    Argues TENS shows real short-term analgesic effect when trials are pooled and dosed adequately.

  • Omron Healthcare

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itConsumer TENS device manufacturer

    Markets OTC TENS units for back, joint, and muscle pain; brand efficacy claims are promotional.

  • iReliev and Compex

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itTENS and e-stim device brands

    Promote wearable and combination TENS/EMS units for recovery; benefit claims are vendor-sourced.

Where the research comes from

Share of published research by country of origin.
PlaceShare of published research
North America38%
Europe30%
Asia24%
Rest of world8%

Research published from: United States.

How we got here

Electrical pain relief is one of medicine's oldest recorded ideas, and its early record is Mediterranean and North African rather than modern European. Ancient Egyptian reliefs depict the Nile electric catfish, and Greek writers associated with Hippocrates noted medical uses of the Mediterranean torpedo ray. Around 46 CE the Roman court physician Scribonius Largus, in his Compositiones, described placing a live black torpedo on the body to numb the pain of gout and of headache until the part grew numb, with Galen later echoing the practice. Interest revived in 18th century Europe through electrostatic generators and Galvani and Volta's work on animal electricity, which set off a wave of electrotherapy devices. The modern chapter opens with Melzack and Wall's 1965 gate control theory, which gave a neural rationale for easing pain with non-painful stimulation. The American neurosurgeon C. Norman Shealy applied it from 1967, first implanting dorsal column stimulators and using surface stimulators to screen candidates. Many patients preferred the external device and never returned for the implant, and portable TENS grew into a standalone therapy through the 1970s.

  1. c. 1 CEGreek and Egyptian sources note electric fish, the torpedo ray and Nile catfish, used for headache and pain
  2. 46 CEScribonius Largus records live torpedo-fish shock for gout and headache in the Compositiones
  3. c. 175 CEGalen documents continued medical use of the torpedo ray
  4. 1791Galvani publishes on animal electricity, reviving interest in electrotherapy
  5. 1965Melzack and Wall publish the gate control theory of pain in Science
  6. 1967Shealy performs the first dorsal column stimulator implant and uses surface stimulation to screen patients
  7. 1970sPortable TENS units move into commercial distribution as standalone pain therapy
  8. 1999Sluka group shows spinal opioid blockade prevents TENS analgesia in arthritic rats, supporting an opioid mechanism
  9. 2019Gibson-led overview of Cochrane Reviews rates the chronic-pain evidence very low quality; ACR guideline advises against TENS for knee and hip OA
  10. 2022Johnson meta-TENS pools 381 RCTs and reports moderate-certainty short-term pain reduction

At a glance

Mechanism
Gate control plus endogenous opioid release at the dorsal horn
Typical frequency
Conventional high-frequency 50 to 120 Hz; acupuncture-like 2 to 10 Hz
Largest synthesis
2022 meta-TENS: 381 RCTs, 24,532 adults, moderate-certainty pain drop
Cost range
About $30 basic units to several hundred for wearable models

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about TENS. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources